2025-08-26 - Analysis Report
Okay, here's an analysis of Eli Lilly and Co. (LLY) based on the data provided, presented in a report format.

## Eli Lilly and Co. (LLY) Analysis

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

### 1. Performance vs. S&P 500 (VOO)

**Key Numbers:**

*   **LLY Cumulative Return:** 205.34%
*   **VOO (S&P 500) Cumulative Return:** 38.23%
*   **Absolute Deviation:** 173.7
*   **Relative Deviation:** 48.8 (Indicates current deviation is at the 48.8th percentile of its historical range)

**Analysis:**

LLY has significantly outperformed the S&P 500 (VOO) over the period analyzed. The absolute deviation is substantial, and the relative deviation suggests that while LLY's outperformance is positive, it's not at the extreme upper end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha | Beta | Cap(B) |
|------------|--------|--------|-------|------|--------|
| 2015-2017  | 10.0%  | 56.3%  | 10.0% | 1.0  | 75.7   |
| 2016-2018  | 39.0%  | 58.6%  | 39.0% | 1.0  | 103.7  |
| 2017-2019  | 50.0%  | 58.6%  | 50.0% | 1.0  | 117.8  |
| 2018-2020  | 52.0%  | 58.6%  | 52.0% | 1.0  | 151.4  |
| 2019-2021  | 106.0% | 60.6%  | 105.0%| -0.0 | 247.6  |
| 2020-2022  | 98.0%  | 64.8%  | 109.0%| -0.0 | 328.0  |
| 2021-2023  | 133.0% | 64.8%  | 123.0%| -0.0 | 522.6  |
| 2022-2024  | 150.0% | 72.2%  | 120.0%| -0.0 | 692.1  |
| 2023-2025  | 58.0%  | 76.8%  | 14.0% | 0.0  | 623.3  |

**Analysis:**

*   **CAGR:** Compound Annual Growth Rate shows strong growth, particularly in recent years.
*   **MDD:** Maximum Drawdown indicates the largest peak-to-trough decline during the period.  MDD has generally increased over time
*   **Alpha:**  Consistently positive alpha values demonstrate that LLY's performance exceeds what would be expected based on the market's (S&P 500) performance alone.  Recent Alpha is lower (2023-2025)
*   **Beta:**  Beta near 1.0 in early periods suggests that LLY's price moved roughly in line with the market.  Recent negative beta indicates a degree of inverse correlation with the market.
*   **Cap(B):**  Market capitalization has grown significantly, reflecting the company's growth.

### 2. Recent Price Action

**Key Numbers:**

*   **Last Price:** 695.33
*   **Previous Close:** 711.68
*   **Change:** -2.3%
*   **5-day Moving Average:** 705.10
*   **20-day Moving Average:** 705.88
*   **60-day Moving Average:** 757.13

**Analysis:**

The stock price has recently declined.  The 5-day and 20-day moving averages are close, while the 60-day moving average is significantly higher, suggesting a potential downward trend in the short to medium term. The recent 2.3% drop from the previous close is a notable move.

### 3. Market Risk Indicators and Expected Return

**Key Numbers:**

*   **Market Risk Indicator (MRI):** 0.32 (Low Risk)
*   **RSI:** 35.82
*   **PPO:** 0.60
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (2 shares - Safe - MRI:0.32)
*   **20-day Relative Deviation Change:** +0.4 (Short-term Increase)
*   **Expected Return:** 226.9% (Long-term, vs. S&P 500)

**Analysis:**

*   **MRI:** A low MRI suggests relatively low market risk.
*   **RSI:** An RSI of 35.82 suggests the stock is nearing oversold conditions.
*   **PPO:** The Positive Price Oscillator (PPO) measures the percentage difference between a shorter-term and a longer-term moving average.
*   **Hybrid Signal:** The Hybrid Signal suggests a "Buy" recommendation, allocating 90% of available cash.
*   **20-day Relative Deviation Change:** Recent increase suggests short-term upward momentum relative to the S&P 500.
*   **Expected Return:** The very high expected return indicates significant potential upside over the long term, relative to the S&P 500.

The recent price change of -2.3% should be considered, potentially leading to a more cautious interpretation of the "Buy" signal.

### 4. Recent News & Significant Events

*   **[2025-08-26]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-24]:** Analyst discussions of performance and outlook.
*   **[2025-08-25]:** Notable stock volatility.
*   **[2025-08-22]:** Market experts highlight risks and opportunities.

**Analysis:**

Recent news indicates that LLY is experiencing volatility and is subject to significant market attention and analyst scrutiny. These events should be monitored closely.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-08-07 | 6.3  | 15.56 B$  |
| 2025-05-01 | 3.07 | 12.73 B$  |
| 2024-10-30 | 1.08 | 11.44 B$  |
| 2024-08-08 | 3.29 | 11.30 B$  |
| 2025-08-07 | 3.29 | 11.30 B$  |

**Analysis:**

*   **EPS:** Earnings per Share (EPS) shows strong growth in the most recent quarter (2025-08-07).
*   **Revenue:** Revenue has also shown significant growth, with the latest quarter reporting $15.56B.

The company is demonstrating strong financial performance, with substantial increases in both EPS and Revenue.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.56B   | 84.27%        |
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $18.27B   | 30.98%    |
| 2025-03-31 | $15.76B   | 17.50%    |
| 2024-12-31 | $14.19B   | 31.07%    |
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |

**Analysis:**

*   **Revenue & Profit Margin:**  Both Revenue and Profit Margin have been increasing, indicating improved operational efficiency and strong demand for the company's products. The profit margins are exceptionally high.
*   **Equity & ROE:** Equity is growing, and the Return on Equity (ROE) is generally high, demonstrating the company's ability to generate profit from shareholders' investments.

### 7. Overall Summary and Conclusion

Eli Lilly and Co. (LLY) has demonstrated exceptional performance, significantly outperforming the S&P 500. Recent financial results show strong growth in revenue, EPS, and profitability. The company's high profit margins and ROE suggest efficient operations and effective capital management.

However, the recent price decline and market volatility should be considered. The low MRI suggests low market risk, and the Hybrid Signal currently suggests a "Buy" recommendation. The very high expected return indicates potential long-term upside.

**Overall Recommendation:**

Given the strong financial performance and positive outlook, a long-term investment in LLY could be considered. However, investors should be aware of the recent volatility and monitor news and market conditions closely. A diversified investment strategy is always recommended.
